Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors
Natalie Cook(Manchester Academic Health Science Centre), Ruth Plummer(National Health Service), Simon A. Woodcock(Redx Pharma (United Kingdom)), Alastair Greystoke(Newcastle University), Rille Pihlak(University of Manchester), David M. Wilson(AstraZeneca (Singapore)), Kaiser Anam(Guy's Hospital), Juanita Lopez(Institute of Cancer Research), Sarah P. Blagden(Churchill Hospital), Craig Tilston(Redx Pharma (United Kingdom)), Farasat Kazmi(University of Oxford), Debashis Sarker(King's College - North Carolina), Caroline Phillips(Redx Pharma (United Kingdom)), Noor Md Haris(Freeman Hospital), Jane Robertson(AstraZeneca (United Kingdom)), Helen Timmis(4D Pharma (United Kingdom)), Ana Ortego Franco(University of Manchester), Louise Goodwin(Redx Pharma (United Kingdom))
Cited by 3
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406